Metanephrine

Spells of pounding heartbeat, headache, and heavy sweating sometimes come from a tumor that produces adrenaline or related hormones. These tumors are rare, but finding one matters because excess hormone release can cause dangerous blood pressure surges and heart problems. Urine metanephrine can contribute to that investigation.

The distinction is between metanephrine and metanephrines. This result measures one molecule. The established diagnostic tests measure metanephrine together with normetanephrine, either in blood plasma or in a complete urine collection. Their accuracy cannot be assigned to this single result. A tumor that mainly produces noradrenaline can leave metanephrine unremarkable.

Where the Number Comes From

Your adrenal glands sit above your kidneys. Cells in their inner core store adrenaline in tiny sacs, and some of that adrenaline continually escapes into the surrounding cell, where an enzyme converts it to metanephrine. This happens in healthy adrenal tissue as well as in adrenaline-producing tumors. Continuous production is why metanephrine can remain detectable between spells, when adrenaline release has subsided.

Normetanephrine comes from noradrenaline. Much of its production reflects noradrenaline released by sympathetic nerves, which help regulate your fight-or-flight response. Metanephrine more specifically reflects adrenaline metabolism in adrenal tissue. The two results have related uses, but different biological sources.

This urine result uses LC-MS. The laboratory separates chemicals in the sample and identifies them through their molecular signals. The reported unit, mcg/g, expresses metanephrine relative to urine creatinine. Creatinine is a waste product made by muscles. Dividing by it helps account for urine concentration, though differences in creatinine production can also affect the ratio.

Urine contains free metanephrine and metanephrine attached to sulfate. Some assays measure only the free form; others remove the sulfate and measure both forms together. The test information supplied here does not specify which fraction is measured or whether collection is timed. LC-MS identifies the analytical method, but does not settle either of those questions. Those details matter when comparing your result with a study or another laboratory.

Adrenal Tumors That Produce Adrenaline

A pheochromocytoma develops in the adrenal gland's inner core. A paraganglioma develops in related tissue outside the adrenal glands. Their hormone production varies: some produce adrenaline, some mainly noradrenaline, and some produce little of either. Some can spread to other parts of the body.

Paired metanephrine testing is an established clinical tool for finding these tumors. The strongest evidence concerns plasma free metanephrines and 24-hour urinary fractionated metanephrines. Spot urine ratios have supporting clinical studies, but a single metanephrine-to-creatinine result has narrower coverage than those full panels.

Plasma free metanephrines performed better in the large comparison, particularly among people investigated because of an inherited predisposition or an incidental tumor finding. Small tumors can be missed by urine testing. Head and neck paragangliomas also frequently produce little metanephrine or normetanephrine; selected cases need plasma methoxytyramine and imaging to assess disease that these two markers may miss.

In children, an eight-marker urine panel that includes metanephrine has improved detection of neuroblastoma compared with the traditional two-marker panel. That evidence supports the expanded panel. It does not establish isolated metanephrine as a neuroblastoma screening test.

Adrenal Masses Found by Accident

Scans performed for unrelated problems sometimes reveal an adrenal mass. Most are benign. Whether metanephrine testing is needed depends partly on the imaging appearance: current European guidance recommends excluding pheochromocytoma when a lesion does not have the typical features of a benign adrenal adenoma.

An adenoma that contains abundant lipid within its cells can often be recognized on an unenhanced CT scan. This is different from calling any adrenal lump a harmless fatty growth. If an adrenal biopsy is being considered, pheochromocytoma must first be excluded because disturbing a hormone-producing tumor can provoke dangerous hormone release.

Research on Kidney and Heart Health

Two retrospective studies from the same Italian center examined people without a diagnosed pheochromocytoma or paraganglioma. One included about 1,400 people evaluated for possible secondary hypertension or adrenal findings; the other included about 830 people with nonfunctioning adrenal masses. Higher urinary metanephrine was associated with small amounts of albumin leaking into urine.

These studies measured total metanephrine excretion in 24-hour collections using an electrochemical method. They did not study this LC-MS creatinine ratio. The populations could overlap, and in the larger study the metanephrine associations did not remain statistically convincing after excluding people taking certain blood pressure medicines. The findings are preliminary evidence of an association, not validation of a cardiovascular prevention test.

A Swedish study followed 879 people with adrenal adenomas for about ten years. Higher urinary normetanephrine was associated with higher mortality after adjustment for other risk factors; metanephrine was not. That study used 24-hour urine ratios and changed analytical methods during the study period. It does not establish a longevity target for this result, and there is no evidence from these studies that lowering metanephrine itself prevents heart or kidney disease.

When the Number Runs Low

A low urine metanephrine result has no established role as a general measure of adrenal health. In a small study, people with type 1 diabetes and a severely impaired adrenaline response to low blood sugar had plasma metanephrine about a quarter lower than healthy controls. That was a blood measurement in a specific clinical setting. It does not validate low urine metanephrine as a way to diagnose impaired responses to low blood sugar.

When Results Can Be Misleading

• Acute illness and hospital care: stress from serious illness can raise metanephrine-panel results without a tumor. In one study, abnormal 24-hour urine panels occurred in about a third of general ward patients and two thirds of intensive care patients without these tumors. Those rates concern the combined panel, not this isolated ratio.
• Sleep apnea: one study found false-positive urine panels in about a quarter of people with obstructive sleep apnea. Every false-positive elevation involved normetanephrine; metanephrine remained normal. This distinction matters if only one part of your panel is raised.
• Medications and stimulants: some antidepressants and stimulants change hormone production or handling even when the laboratory measures the sample correctly. Tricyclic antidepressants and venlafaxine are especially relevant to normetanephrine. Medication effects should be assessed against the specific molecule and assay.
• Creatinine and collection differences: muscle mass and creatinine production influence a creatinine-adjusted ratio. Dividing by creatinine does not repair an incomplete 24-hour collection. A creatinine concentration alone cannot prove that every void was collected.
• Kidney function: impaired kidney function can change metabolite handling and complicate urine interpretation, especially in advanced kidney disease.
• LC-MS interference: this method avoids many interferences seen with older assays, but other chemicals in urine can weaken or overlap the measured signal. Laboratories use internal controls and additional analytical checks to identify such problems. LC-MS does not remove physiological effects of illness or medication.

The original cefazolin interference report involved electrochemical detection, not LC-MS. Likewise, precision reported for one laboratory method cannot be applied to every assay. A change between tests can reflect collection, biology, or analytical variation, and a stable isolated metanephrine result does not exclude a tumor that produces a different hormone.